Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine

Journal of the American College of Cardiology

Volumn 49, Issue 3, 2007, Pages 279-289

  Anwaruddin, Saif ^a   Askari, Arman T ^a   Topol, Eric J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ATORVASTATIN; CD40 LIGAND; EPTIFIBATIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; TROGLITAZONE; TROPONIN; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; CELL INTERACTION; CLINICAL ASSESSMENT; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; ELECTROCARDIOGRAPHY; HUMAN; LEUKOCYTE; MOLECULAR INTERACTION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING; THROMBOCYTE; VASCULAR ENDOTHELIUM;

ANGINA, UNSTABLE; C-REACTIVE PROTEIN; CD40 LIGAND; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MOLECULAR BIOLOGY; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; P-SELECTIN; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TROPONIN T;

EID: 33846262006     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.08.051     Document Type: Review

References (101)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
2. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., and Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 347 (2002) 5-12
3. Topol E.J. Simon Dack lecture. The genomic basis of myocardial infarction. J Am Coll Cardiol 46 (2005) 1456-1465
4. Morrow D.A., and Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 108 (2003) 250-252
5. Mutin M., Canavy I., Blann A., Bory M., Sampol J., and Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 93 (1999) 2951-2958
6. Montalescot G., Collet J.P., Choussat R., Ankri A., and Thomas D. A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients. Int J Cardiol 72 (2000) 293-294
7. Andre P., Denis C.V., Ware J., et al. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 96 (2000) 3322-3328
8. Eto K., Isshiki T., Yamamoto H., et al. AJvW-2, an anti-vWF monoclonal antibody, inhibits enhanced platelet aggregation induced by high shear stress in platelet-rich plasma from patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 19 (1999) 877-882
9. Ray K.K., Morrow D.A., Gibson C.M., Murphy S., Antman E.M., and Braunwald E. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J 26 (2005) 440-446
10. Montalescot G., Philippe F., Ankri A., et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE trial. Circulation 98 (1998) 294-299
11. Wagner A.H., Guldenzoph B., Lienenluke B., and Hecker M. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol 24 (2004) 715-720
12. Andre P., Prasad K.S., Denis C.V., et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 8 (2002) 247-252
13. Furman M.I., Krueger L.A., Linden M.D., Barnard M.R., Frelinger III A.L., and Michelson A.D. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 43 (2004) 2319-2325
14. Urbich C., Dernbach E., Aicher A., Zeiher A.M., and Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 106 (2002) 981-986
15. Varo N., de Lemos J.A., Libby P., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
16. Kinlay S., Schwartz G.G., Olsson A.G., et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110 (2004) 386-391
17. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
18. Schonbeck U., Gerdes N., Varo N., et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 106 (2002) 2888-2893
19. Sanguigni V., Pignatelli P., Lenti L., et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111 (2005) 412-419
20. Varo N., Vicent D., Libby P., et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107 (2003) 2664-2669
21. Semb A.G., van Wissen S., Ueland T., et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 41 (2003) 275-279
22. Furman M.I., Krueger L.A., Linden M.D., et al. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost 3 (2005) 312-320
23. Nannizzi-Alaimo L., Alves V.L., and Phillips D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 107 (2003) 1123-1128
24. Quinn M.J., Plow E.F., and Topol E.J. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?. Circulation 106 (2002) 379-385
25. Ridker P.M., Buring J.E., and Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 103 (2001) 491-495
26. Guray U., Erbay A.R., Guray Y., et al. Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis. Int J Cardiol 96 (2004) 235-240
27. Freedman J.E., and Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 105 (2002) 2130-2132
28. Menon V., Lessard D., Yarzebski J., Furman M.I., Gore J.M., and Goldberg R.J. Leukocytosis and adverse hospital outcomes after acute myocardial infarction. Am J Cardiol 92 (2003) 368-372
29. Sabatine M.S., Morrow D.A., Cannon C.P., et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction 18 trial) substudy. J Am Coll Cardiol 40 (2002) 1761-1768
30. Madjid M., Awan I., Willerson J.T., and Casscells S.W. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 44 (2004) 1945-1956
31. Naruko T., Ueda M., Haze K., et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106 (2002) 2894-2900
32. Podrez E.A., Febbraio M., Sheibani N., et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 105 (2000) 1095-1108
33. Abu-Soud H.M., and Hazen S.L. Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem 275 (2000) 5425-5430
34. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349 (2003) 1595-1604
35. Askari A.T., Brennan M.L., Zhou X., et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 197 (2003) 615-624
36. Dewald O., Zymek P., Winkelmann K., et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96 (2005) 881-889
37. de Lemos J.A., Morrow D.A., Sabatine M.S., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107 (2003) 690-695
38. de Nooijer R., von der Thusen J.H., Verkleij C.J., et al. Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice. Arterioscler Thromb Vasc Biol 24 (2004) 2313-2319
39. Mallat Z., Corbaz A., Scoazec A., et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 89 (2001) E41-E45
40. Chalikias G.K., Tziakas D.N., Kaski J.C., et al. Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis 182 (2005) 135-143
41. Shah P.K., Falk E., Badimon J.J., et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92 (1995) 1565-1569
42. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
43. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
44. Bayes-Genis A., Conover C.A., Overgaard M.T., et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 345 (2001) 1022-1029
45. Lund J., Qin Q.P., Ilva T., et al. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 108 (2003) 1924-1926
46. Kinoshita M., Miyamoto T., Ohashi N., Sasayama S., and Matsumori A. Thrombosis increases circulatory hepatocyte growth factor by degranulation of mast cells. Circulation 106 (2002) 3133-3138
47. Hata N., Matsumori A., Yokoyama S., et al. Hepatocyte growth factor and cardiovascular thrombosis in patients admitted to the intensive care unit. Circ J 68 (2004) 645-649
48. Yasuda S., Goto Y., Baba T., et al. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol 36 (2000) 115-121
49. Zhou X., Nicoletti A., Elhage R., and Hansson G.K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102 (2000) 2919-2922
50. Fu X., Kassim S.Y., Parks W.C., and Heinecke J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 276 (2001) 41279-41287
51. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
52. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286 (2001) 2136-2142
53. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89 (2001) E1-E7
54. Fadini G.P., Miorin M., Facco M., et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 45 (2005) 1449-1457
55. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353 (2005) 999-1007
56. Jackson K.A., Majka S.M., Wang H., et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 107 (2001) 1395-1402
57. Kocher A.A., Schuster M.D., Szabolcs M.J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7 (2001) 430-436
58. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
59. Kumada M., Kihara S., Ouchi N., et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109 (2004) 2046-2049
60. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
61. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
62. Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107 (2003) 671-674
63. Schulze M.B., Shai I., Rimm E.B., Li T., Rifai N., and Hu F.B. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54 (2005) 534-539
64. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
65. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
66. Kojima S., Funahashi T., Sakamoto T., et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 89 (2003) 667
67. Sinkovic A., and Pogacar V. Risk stratification in patients with unstable angina and/or non-ST-elevation myocardial infarction by Troponin T and plasminogen-activator-inhibitor-1 (PAI-1). Thromb Res 114 (2004) 251-257
68. Collet J.P., Montalescot G., Vicaut E., et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 108 (2003) 391-394
69. Inoue M., Itoh H., Ueda M., et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98 (1998) 2108-2116
70. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., and Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7 (2001) 425-429
71. Celletti F.L., Hilfiker P.R., Ghafouri P., and Dake M.D. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 37 (2001) 2126-2130
72. Moulton K.S., Heller E., Konerding M.A., Flynn E., Palinski W., and Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99 (1999) 1726-1732
73. Zhao Q., Ishibashi M., Hiasa K., Tan C., Takeshita A., and Egashira K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension 44 (2004) 264-270
74. Alber H.F., Dulak J., Frick M., et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol 39 (2002) 1951-1955
75. Biasucci L.M., Liuzzo G., Fantuzzi G., et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99 (1999) 2079-2084
76. Bhagat K., and Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 96 (1997) 3042-3047
77. Rajavashisth T.B., Xu X.P., Jovinge S., et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 99 (1999) 3103-3109
78. Branen L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., and Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 24 (2004) 2137-2142
79. Waehre T., Halvorsen B., Damas J.K., et al. Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 32 (2002) 803-810
80. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., and Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 (2005) 932-939
81. Bhatt D.L., and Topol E.J. Need to test the arterial inflammation hypothesis. Circulation 106 (2002) 136-140
82. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
83. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99 (1999) 855-860
84. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 (2001) 1194-1197
85. Torzewski M., Rist C., Mortensen R.F., et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20 (2000) 2094-2099
86. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
87. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
88. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100 (1999) 230-235
89. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
90. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
91. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
92. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
93. Ridker P.M. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 148 (2004) S19-S26
94. Ridker P.M. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108 (2003) 2292-2297
95. Pepys M.B., Hirschfield G.M., Tennent G.A., et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440 (2006) 1217-1221
96. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
97. Hakonarson H., Thorvaldsson S., Helgadottir A., et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293 (2005) 2245-2256
98. Cohen J.C., Boerwinkle E., Mosley Jr. T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006) 1264-1272
99. Komulainen K., Alanne M., Auro K., et al. Risk alleles of USF1 gene predict cardiovascular disease of women in two prospective studies. PLoS Genet 2 (2006) e69
100. Ginsburg G.S., Donahue M.P., and Newby L.K. Prospects for personalized cardiovascular medicine: the impact of genomics. J Am Coll Cardiol 46 (2005) 1615-1627
101. Ahn E.R., Lander G., Jy W., et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114 (2004) 143-148